Page 92 - Read Online
P. 92

Ida et al. J Cancer Metastasis Treat 2018;4:22  I  http://dx.doi.org/10.20517/2394-4722.2017.75                                    Page 7 of 9

               Financial support and sponsorship
               None.


               Conflicts of interest
               Authors declare that they have no conflicts of interest.


               Patient consent
               Not applicable.


               Ethics approval
               Not applicable.

               Copyright
               © The Author(s) 2018.


               REFERENCES
               1.   Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer 2017;20:1-19.
               2.   Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D; ESMO Guidelines Committee. Gastric cancer: ESMO Clinical
                   Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016;27:v38-49.
               3.   Ajani JA, D’Amico TA, Almhanna K, Bentrem DJ, Chao J, Das P, Denlinger CS, Fanta P, Farjah F, Fuchs CS, Gerdes H, Gibson M,
                   Glasgow RE, Hayman JA, Hochwald S, Hofstetter WL, Ilson DH, Jaroszewski D, Johung KL, Keswani RN, Kleinberg LR, Korn
                   WM, Leong S, Linn C, Lockhart AC, Ly QP, Mulcahy MF, Orringer MB, Perry KA, Poultsides GA, Scott WJ, Strong VE, Washington
                   MK, Weksler B, Willett CG, Wright CD, Zelman D, McMillian N, Sundar H. Gastric Cancer, Version 3.2016, NCCN Clinical Practice
                   Guidelines in Oncology. J Natl Compr Canc Netw 2016;14:v1286-312.
               4.   Sasako M, Sano T, Yamamoto S, Kurokawa Y, Nashimoto A, Kurita A, Hiratsuka M, Tsujinaka T, Kinoshita T, Arai K, Yamamura Y,
                   Okajima K. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med 2008;359:453-62.
               5.   Tokunaga M, Ohyama S, Hiki N, Fukunaga T, Aikou S, Yamaguchi T. Can superextended lymph node dissection be justified for gastric
                   cancer with pathologically positive para-aortic lymph nodes? Ann Surg Oncol 2010;17:2031-6.
               6.   Tsuburaya A, Mizusawa J, Tanaka Y, Fukushima N, Nashimoto A, Sasako M. Neoadjuvant chemotherapy with S-1 and cisplatin
                   followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis. Br J Surg
                   2014;101:653-60.
               7.   Wang Y, Yu YY, Li W, Feng Y, Hou J, Ji Y, Sun YH, Shen KT, Shen ZB, Qin XY, Liu TS. A phase II trial of Xeloda and oxaliplatin
                   (XELOX) neo-adjuvant chemotherapy followed by surgery for advanced gastric cancer patients with para-aortic lymph node metastasis.
                   Cancer Chemother Pharmacol 2014;73:1155-61.
               8.   Fukagawa T, Katai H, Mizusawa J, Nakamura K, Sano T, Terashima M, Ito S, Yoshikawa T, Fukushima N, Kawachi Y, Kinoshita T,
                   Kimura Y, Yabusaki H, Nishida Y, Iwasaki Y, Lee SW, Yasuda T, Sasako M. A prospective multi-institutional validity study to evaluate
                   the accuracy of clinical diagnosis of pathological stage III gastric cancer (JCOG1302A). Gastric Cancer 2018;21:68-73.
               9.   Hasegawa S, Yoshikawa T, Shirai J, Fujikawa H, Cho H, Doiuchi T, Yoshida T, Sato T, Oshima T, Yukawa N, Rino Y, Masuda M,
                   Tsuburaya A. A prospective validation study to diagnose serosal invasion and nodal metastases of gastric cancer by multidetector-row
                   CT. Ann Surg Oncol 2013;20:2016-22.
               10.  Marrelli D, Mazzei MA, Pedrazzani C, Di Martino M, Vindigni C, Corso G, Morelli E, Volterrani L, Roviello F. High accuracy of
                   multislices computed tomography (MSCT) for para-aortic lymph node metastases from gastric cancer: a prospective single-center study.
                   Ann Surg Oncol 2011;18:2265-72.
               11.  Folprecht G, Gruenberger T, Bechstein W, Raab HR, Weitz J, Lordick F, Hartmann, JT, Stoehlmacher-Williams J, Lang H, Trarbach T,
                   Liersch T, Ockert D, Jaeger D, Steger U, Suedhoff T, Rentsch A, Kohne CH. Survival of patients with initially unresectable colorectal
                   liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study). Ann Oncol
                   2014;25:1018-25.
               12.  Takemura N, Saiura A, Koga R, Arita J, Yoshioka R, Ono Y, Hiki N, Sano T, Yamamoto J, Kokudo N, Yamaguchi T. Long-term
                   outcomes after surgical resection for gastric cancer liver metastasis: an analysis of 64 macroscopically complete resections. Langenbecks
                   Arch Surg 2012;397:951-7.
               13.  Kinoshita T, Kinoshita T, Saiura A, Esaki M, Sakamoto H, Yamanaka T. Multicentre analysis of long-term outcome after surgical
                   resection for gastric cancer liver metastases. Br J Surg 2015;102:102-7.
               14.  Tiberio GA, Baiocchi GL, Morgagni P, Marrelli D, Marchet A, Cipollari C, Graziosi L, Ministrini S, Vittimberga G, Donini A, Nitti D,
                   Roviello F, Coniglio A, de Manzoni G. Gastric cancer and synchronous hepatic metastases: is it possible to recognize candidates to R0
                   resection? Ann Surg Oncol 2015;22:589-96.
   87   88   89   90   91   92   93   94   95   96   97